← Back to Search

Diagnostic Test

Dual Energy CT for Computed Tomography (DECT-ICH Trial)

N/A

Recruiting

Research Sponsored by University of Manitoba

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients greater than or equal to 18 years of age presenting with acute ischemic stroke (AIS) that are candidates for 1) thrombolysis (tPA) and/or 2) endovascular thrombectomy (EVT)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up assessed up to 90 days

Awards & highlights

DECT-ICH Trial Summary

This trial aims to study the use of a special type of CT scan called DECT in patients who have had a stroke and received treatment. The main questions the trial wants to answer are: 1

Who is the study for?

This trial is for adults over 18 with acute ischemic stroke who are eligible for clot-busting medication or a procedure to remove the clot. It's not suitable for those who don't meet these specific conditions.Check my eligibility

What is being tested?

The study tests if Dual-Energy Computed Tomography (DECT) can better identify bleeding in the brain or leakage of contrast dye compared to standard CT scans in stroke patients after treatment.See study design

What are the potential side effects?

Since DECT is a type of CT scan, potential side effects may include exposure to radiation, which carries a small risk of cancer and allergic reactions to contrast material used during the scan.

DECT-ICH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

DECT-ICH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ assessed up to 90 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~assessed up to 90 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed up to 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The presence or absence of intracerebral hemorrhage on DECT scans

Secondary outcome measures

Length of Stay

Level of Disability at 90 days post-stroke

Type of Intracerebral Hemorrhage (ICH)

DECT-ICH Trial Design

1Treatment groups

Experimental Treatment

Group I: Dual Energy CTExperimental Treatment1 Intervention

Patients with acute stroke who receive intervention in the form of thrombolysis or EVT will receive dual-energy CT at the 24-hour mark in lieu of conventional single-energy CT.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Dual Energy CT

2014

N/A

~100

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of ManitobaLead Sponsor

595 Previous Clinical Trials

199,281 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the recruitment phase for this medical study currently ongoing?

"Indeed, the information provided on clinicaltrials.gov confirms that this trial is currently accepting applications. The trial was initially listed on October 17th, 2023 and was most recently updated on January 17th, 2024. This study aims to enroll a total of 200 participants from a single site."

Answered by AI

How many individuals are currently enrolled in this research trial?

"Indeed, the information available on clinicaltrials.gov confirms that this trial is currently seeking eligible participants. The initial posting of the clinical trial was on October 17th, 2023 and it underwent its most recent update on January 17th, 2024. The study aims to enroll a total of 200 patients from a single designated location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

DECT for Differentiating Intracerebral Hemorrhage From Contrast Extravasation

Jai Shankar 2023. "DECT for Differentiating Intracerebral Hemorrhage From Contrast Extravasation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05675774.